Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

BACKGROUND: Recombinant tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumour-selective apoptosis in various pre-clinical models by binding its specific receptors expressed on cancer cells. Mapatumumab is a fully human monoclonal antibody that is agonistic to the TRAIL Rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Trarbach, T, Moehler, M, Heinemann, V, Köhne, C-H, Przyborek, M, Schulz, C, Sneller, V, Gallant, G, Kanzler, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822942/
https://www.ncbi.nlm.nih.gov/pubmed/20068564
http://dx.doi.org/10.1038/sj.bjc.6605507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822942/
https://www.ncbi.nlm.nih.gov/pubmed/20068564
http://dx.doi.org/10.1038/sj.bjc.6605507

Ejemplares similares